This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zoetis (ZTS) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.
Zoetis (ZTS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 21.15% and 7.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.
Top Stock Reports for Apple, Alphabet & BlackRock
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Alphabet (GOOGL), and BlackRock (BLK).
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.
Sanofi (SNY) Acquires Tidal to Aid mRNA-Based Research Platform
by Zacks Equity Research
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.
The Zacks Analyst Blog Highlights: Apple, Alibaba Group, AT&T, Intuitive Surgical and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Alibaba Group, AT&T, Intuitive Surgical and Zoetis
Top Stock Reports for Apple, Alibaba & AT&T
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Alibaba Group Holding Limited (BABA) and AT&T Inc. (T).
Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.
Novartis (NVS) Posts Positive Data From Prostate Cancer Study
by Zacks Equity Research
Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.
Zoetis (ZTS) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results
by Zacks Equity Research
Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.
Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B
by Zacks Equity Research
Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.
The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tapestry, Ulta Beauty, Synchrony Financial, CDW Corp and Zoetis
5 Top-Ranked Stocks Backed by Women Power
by Sweta Killa
We have highlighted some top-ranked stocks from the S&P 500 that are headed by female CEOs and have massive upside potential in the coming years.
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.